FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386419705> ?p ?o ?g. }

• W4386419705 abstract "Multiple myeloma (MM) patients with high-risk cytogenetic abnormalities have inferior survival outcomes and are underrepresented in clinical trials. There is scarce data on MM patients with more than one high-risk cytogenetic aberration (ie, ultra- high-risk MM). This study was conducted to evaluate outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent autologous hematopoietic stem cell transplantation (autoHCT). We conducted a retrospective single-center chart review analysis of adult patients with ultra-high-risk MM who underwent autoHCT between 2008 and 2018 at MD Anderson Cancer Center. High-risk cytogenetics were defined as del(17p), t(4;14), t(14;16), or 1q21 gain or amplification (1q+) by fluorescence in situ hybridization. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Seventy-nine patients with two or more high-risk cytogenetic abnormalities were included in our analysis. The median age of 61 years (range, 33.5 to 76.5 years), and 57% were female. Sixty-seven patients had two high-risk cytogenetic abnormalities, and 12 patients had three high-risk cytogenetic abnormalities. The most common combinations of high-risk abnormalities were [1q+, t(4:14)] (n = 25; 32%) and [1q+, del17p] (n = 21; 27%). The majority of patients received either bortezomib, lenalidomide, and dexamethasone (48%) or carfilzomib, lenalidomide, and dexamethasone (16%) as induction therapy. Prior to autoHCT, 52 patients (66%) achieved a very good partial response or better (≥VGPR), whereas 23 patients (29%) achieved minimal residual disease (MRD)-negative ≥VGPR. Fifty-six patients (71%) received post-transplantation maintenance therapy. Thirty-six patients (46%) achieved MRD-negative ≥VGPR at day +100 after autoHCT, and 40 patients (51%) did so at best post-transplantation response. With a median follow-up in surviving patients of 38.3 months (range, 11.9 to 104.8 months), the median PFS and OS in the entire cohort were 22.9 months and 71.5 months, respectively. For the subset of patients with three HR abnormalities, the median PFS was 15.6 months and median OS was 28.0 months. In multivariate analysis, achieving MRD-negative ≥VGPR prior to autoHCT was associated with improved PFS (hazard ratio [HR], .42; P = .045), whereas male sex (HR, .15; P = .009) and achieving MRD-negative ≥VGPR post-autoHCT (HR, .27; P = .026) were associated with improved OS. In conclusion, patients with ultra-high-risk MM have a median PFS of <24 months with the current standard of care that includes consolidation with autoHCT. These patients may benefit from earlier use of newer treatment modalities, such as chimeric antigen receptor T cell therapy and bispecific antibodies." @default.
• W4386419705 created "2023-09-05" @default.
• W4386419705 creator A5008785159 @default.
• W4386419705 creator A5015342719 @default.
• W4386419705 creator A5020558212 @default.
• W4386419705 creator A5022871468 @default.
• W4386419705 creator A5029237145 @default.
• W4386419705 creator A5037077714 @default.
• W4386419705 creator A5037963602 @default.
• W4386419705 creator A5038186608 @default.
• W4386419705 creator A5038235561 @default.
• W4386419705 creator A5038619722 @default.
• W4386419705 creator A5048362577 @default.
• W4386419705 creator A5048913229 @default.
• W4386419705 creator A5055885795 @default.
• W4386419705 creator A5055929208 @default.
• W4386419705 creator A5060313982 @default.
• W4386419705 creator A5068834306 @default.
• W4386419705 creator A5069460930 @default.
• W4386419705 creator A5069676375 @default.
• W4386419705 creator A5071516639 @default.
• W4386419705 creator A5086795872 @default.
• W4386419705 date "2023-09-01" @default.
• W4386419705 modified "2023-10-10" @default.
• W4386419705 title "Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma" @default.
• W4386419705 cites W2046408556 @default.
• W4386419705 cites W2125721471 @default.
• W4386419705 cites W2128084036 @default.
• W4386419705 cites W2175133478 @default.
• W4386419705 cites W2318069817 @default.
• W4386419705 cites W2486629951 @default.
• W4386419705 cites W2505446618 @default.
• W4386419705 cites W2572301919 @default.
• W4386419705 cites W2622796688 @default.
• W4386419705 cites W2887448109 @default.
• W4386419705 cites W3011070604 @default.
• W4386419705 cites W3017057237 @default.
• W4386419705 cites W3045223998 @default.
• W4386419705 cites W3133229959 @default.
• W4386419705 cites W3134398991 @default.
• W4386419705 cites W3158356424 @default.
• W4386419705 cites W3176532045 @default.
• W4386419705 cites W3207918641 @default.
• W4386419705 cites W4221051888 @default.
• W4386419705 cites W4282033105 @default.
• W4386419705 cites W4311451985 @default.
• W4386419705 cites W4318189277 @default.
• W4386419705 cites W4324130228 @default.
• W4386419705 doi "https://doi.org/10.1016/j.jtct.2023.08.031" @default.
• W4386419705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37673125" @default.
• W4386419705 hasPublicationYear "2023" @default.
• W4386419705 type Work @default.
• W4386419705 citedByCount "0" @default.
• W4386419705 crossrefType "journal-article" @default.
• W4386419705 hasAuthorship W4386419705A5008785159 @default.
• W4386419705 hasAuthorship W4386419705A5015342719 @default.
• W4386419705 hasAuthorship W4386419705A5020558212 @default.
• W4386419705 hasAuthorship W4386419705A5022871468 @default.
• W4386419705 hasAuthorship W4386419705A5029237145 @default.
• W4386419705 hasAuthorship W4386419705A5037077714 @default.
• W4386419705 hasAuthorship W4386419705A5037963602 @default.
• W4386419705 hasAuthorship W4386419705A5038186608 @default.
• W4386419705 hasAuthorship W4386419705A5038235561 @default.
• W4386419705 hasAuthorship W4386419705A5038619722 @default.
• W4386419705 hasAuthorship W4386419705A5048362577 @default.
• W4386419705 hasAuthorship W4386419705A5048913229 @default.
• W4386419705 hasAuthorship W4386419705A5055885795 @default.
• W4386419705 hasAuthorship W4386419705A5055929208 @default.
• W4386419705 hasAuthorship W4386419705A5060313982 @default.
• W4386419705 hasAuthorship W4386419705A5068834306 @default.
• W4386419705 hasAuthorship W4386419705A5069460930 @default.
• W4386419705 hasAuthorship W4386419705A5069676375 @default.
• W4386419705 hasAuthorship W4386419705A5071516639 @default.
• W4386419705 hasAuthorship W4386419705A5086795872 @default.
• W4386419705 hasConcept C126322002 @default.
• W4386419705 hasConcept C141071460 @default.
• W4386419705 hasConcept C143998085 @default.
• W4386419705 hasConcept C2776063141 @default.
• W4386419705 hasConcept C2776364478 @default.
• W4386419705 hasConcept C2776694085 @default.
• W4386419705 hasConcept C2777408962 @default.
• W4386419705 hasConcept C2777478702 @default.
• W4386419705 hasConcept C2778461978 @default.
• W4386419705 hasConcept C2779050716 @default.
• W4386419705 hasConcept C2779823535 @default.
• W4386419705 hasConcept C2780073493 @default.
• W4386419705 hasConcept C2780775027 @default.
• W4386419705 hasConcept C2911091166 @default.
• W4386419705 hasConcept C71924100 @default.
• W4386419705 hasConceptScore W4386419705C126322002 @default.
• W4386419705 hasConceptScore W4386419705C141071460 @default.
• W4386419705 hasConceptScore W4386419705C143998085 @default.
• W4386419705 hasConceptScore W4386419705C2776063141 @default.
• W4386419705 hasConceptScore W4386419705C2776364478 @default.
• W4386419705 hasConceptScore W4386419705C2776694085 @default.
• W4386419705 hasConceptScore W4386419705C2777408962 @default.
• W4386419705 hasConceptScore W4386419705C2777478702 @default.
• W4386419705 hasConceptScore W4386419705C2778461978 @default.
• W4386419705 hasConceptScore W4386419705C2779050716 @default.
• W4386419705 hasConceptScore W4386419705C2779823535 @default.

• next